SC-002 in Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma

A Phase 1a/1b Dose Escalation and Expansion Study of Single-agent SC-002 in Subjects With Relapsed or Refractory Small Cell Lung Cancer and Large Cell Neuroendocrine Carcinoma


Lead Sponsor: Stemcentrx

Source Stemcentrx
Brief Summary

This is a Phase 1a/1b study of SC-002 in patients with relapsed small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC). SC-002 is an antibody-drug conjugate (ADC) comprised of a monoclonal antibody linked to a potent chemotherapy. The purpose of this study is to assess the safety and tolerability of SC-002 at different dose levels, to determine the highest dose of SC-002 that can be given to patients with SCLC or LCNEC, to evaluate the side effects of SC-002, and to assess the anti-cancer activity of SC-002.

Detailed Description

Part 1A is a dose escalation study in patients with small cell lung cancer or large cell neuroendocrine carcinoma with cytologically confirmed, limited or extensive SCLC or LCNEC that have relapsed or refractory limited or extensive disease following no more than 2 prior chemotherapy regimens. Part 1B is an expansion study where patients will be enrolled and treated in order to further characterize safety and preliminary efficacy in patients with SCLC or LCNEC and further characterize PK, immunogenicity and target expression and possible relationship to clinical outcome.

Overall Status Terminated
Start Date 2015-06-01
Completion Date 2018-08-23
Primary Completion Date 2018-08-23
Phase Phase 1
Study Type Interventional
Primary Outcome
Measure Time Frame
Maximum tolerated dose 6 months
Number of subjects with adverse events as a measure of safety and tolerability 6 months
Secondary Outcome
Measure Time Frame
Pharmacokinetics of SC-002 Cycle 1 and 4: days 1, 2, 4, 8, 15; Cycles 2, 3, and 5: day 1 only
RECIST v1.1 assessed objective response rate 6 months
Enrollment 35

Intervention Type: Drug

Intervention Name: SC-002

Description: SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks

Arm Group Label: SC-002



Inclusion Criteria: - Histologically or cytologically confirmed SCLC (either limited or extensive disease) or LCNEC, that has relapsed from the most current treatment or was refractory to treatment - Evidence of progressive disease during or following no more than 2 prior chemotherapy regimens - Measurable disease as defined by RECIST - ECOG performance status of 0 or 1 - Adequate hematological and organ function as confirmed by laboratory values - Treatment with anticancer/investigational drugs, therapy ≤ 4 weeks prior to first dose of SC-002 Exclusion Criteria: - Active central nervous system metastases - Uncontrolled cardiac disease - Positive serology for hepatitis B or hepatitis C or known HIV infection - Presence of any condition that may increase the risks associated with study participation and interfere with the interpretation of study results



Minimum Age:

18 Years

Maximum Age:


Healthy Volunteers:


Overall Official
Last Name Role Affiliation
Julia Lawrence, D.O. Study Director Novella Clinical
Overall Contact Contact information is only displayed when the study is recruiting subjects.
| Ann Arbor, Michigan, 48109, United States
| Saint Louis, Missouri, 63110, United States
| New York, New York, 10065, United States
| Nashville, Tennessee, 37203, United States
Location Countries

United States

Verification Date


Responsible Party

Type: Sponsor

Has Expanded Access No
Condition Browse
Number Of Arms 1
Arm Group

Label: SC-002

Type: Experimental

Description: Part 1A (Dose Escalation) - IV infusion; safety data will be reviewed prior to dose escalation decision. Dose escalation will complete when recommended dose (RD) is determined. RD will be the maximum tolerated dose (MTD) or lower dose that provides adequate PK exposure, immunogenicity, and preliminary evidence of antitumor activity with tolerability. Part 1B (Dose Expansion) - IV infusion; once MTD and/or RD has been determined in Part 1A, an expansion cohort of approximately 60 patients with SCLC or LCNEC will be enrolled to further characterize the safety profile and clinical activity of the RD. Patients may continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent.

Study Design Info

Allocation: N/A

Intervention Model: Single Group Assignment

Primary Purpose: Treatment

Masking: None (Open Label)

This information was retrieved directly from the website without any changes. If you have any requests to change, remove or update your study details, please contact [email protected]. As soon as a change is implemented on, this will be updated automatically on our website as well.

Clinical Research News